Rathish Devarajan, Jayasumana Channa, Agampodi Suneth
Department of Pharmacology, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Saliyapura, Sri Lanka.
Department of Community Medicine, Faculty of Medicine and Allied Sciences, Rajarata University of Sri Lanka, Saliyapura, Sri Lanka.
J Health Popul Nutr. 2019 Jan 23;38(1):3. doi: 10.1186/s41043-019-0160-x.
Higher efficacy of incretin-based therapies for type 2 diabetes mellitus has been reported from Asia. Pancreatitis and hepatitis have also been suspected to occur due to dipeptidyl peptidase-4 inhibitor (DPP4I) treatment. The present study aims at comparing selected biochemical parameters among DPP4 inhibitor users and other oral hypoglycaemic drug users.
Patients were recruited from the State Pharmaceutical Corporation, Anuradhapura, Sri Lanka, for a comparative cross-sectional study. Two groups were involved: "DPP4I" user group (n = 63) and "other oral hypoglycaemic" user group (n = 126). Mann-Whitney U test was performed to find a significant difference (p < 0.05) in the distributions of HbA, pancreatic amylase, serum lipase, AST and ALT levels between the two groups.
Contradicting to previous Asian studies, distribution of HbA (p = 0.569) between anti-diabetic regimes with and without DPP4 inhibitors showed no significant difference. Also, amylase (p = 0.171), AST (p = 0.238) and ALT (p = 0.347) failed to show significance. However, lipase was significantly (p = 0.012) high in the DPP4I group.
The study showed a significantly higher lipase level among the DPP4I users in comparison to other oral hypoglycaemic drug users, and possible reasons were discussed.
亚洲地区已有报道称基于肠促胰岛素的疗法对2型糖尿病疗效更高。胰腺炎和肝炎也被怀疑是由二肽基肽酶-4抑制剂（DPP4I）治疗引起的。本研究旨在比较DPP4抑制剂使用者与其他口服降糖药使用者之间选定的生化参数。
从斯里兰卡阿努拉德普勒的国家制药公司招募患者进行一项比较性横断面研究。涉及两组：“DPP4I”使用者组（n = 63）和“其他口服降糖药”使用者组（n = 126）。进行曼-惠特尼U检验以发现两组之间血红蛋白A（HbA）、胰腺淀粉酶、血清脂肪酶、谷草转氨酶（AST）和谷丙转氨酶（ALT）水平分布的显著差异（p < 0.05）。
与之前的亚洲研究结果相反，使用和未使用DPP4抑制剂的抗糖尿病治疗方案之间HbA的分布（p = 0.569）无显著差异。此外，淀粉酶（p = 0.171）、AST（p = 0.238）和ALT（p = 0.347）也未显示出显著性差异。然而，DPP4I组的脂肪酶水平显著升高（p = 0.012）。
该研究表明，与其他口服降糖药使用者相比，DPP4I使用者的脂肪酶水平显著更高，并对可能的原因进行了讨论。
